Superior survival of females among 10 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 583-589

  de Vries, E ^a,b   Nijsten, T E C ^a,c   Visser, O ^d   Bastiaannet, E ^e   van Hattem, S ^a,c   Janssen Heijnen, M L ^b   Coebergh, J W W ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b The Netherlands   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d Integraal Kankercentrum Amsterdam   (Netherlands)

^e Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

Gender difference; Melanoma; Prognosis; Relative survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NETHERLANDS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SKIN ULCER; SURVIVAL RATE; SURVIVAL TIME;

FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; SEX DISTRIBUTION; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 40149093090     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm498     Document Type: Article

References (44)

1. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
2. Koh HK, Geller AC. Melanoma and skin cancer control: An international perspective. Cancer Control 1995; 2: 385-391.
3. Krol S, Keljser LM, van der Rhee HJ, Welvaart K. Screening for skin cancer in The Netherlands. Acta Derm Venereol 1991; 71: 317-321.
4. de Vries E, Houterman S, Janssen-Heijnen M et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol 2007; 18: 1110-1116.
5. Downing A, Newton-Bishop JA, Forman D, Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006; 95: 91-95.
6. Scoggins CR, Ross MI, Reintgen DS et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243: 693-698; discussion 698-700.
7. Coory M, Baade P, Aitken JI et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006; 17: 21-27.
8. de Vries E, Bray F, Coebergh JWW et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality, but recent stabilisations in western Europe and de Scandinavia, Int J Cancer 2003; 107: 119-126.
9. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous. melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93: 678-683.
10. ClarK LN, Shin DB, Troxel AB et al. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol 2007; 56: 768-773.
11. Masback A, Olsson H, Westerdahl J et al. Prognostic factors in invasive cutaneous malignant melanoma: A population-based study and review. Melanoma Res 2001; 11: 435-445.
12. Schuchter L, Schultz DJ, 'Synnestvedt M et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 1996; 125: 369-375.
13. Thorn M, Penten F; Bergstrom R et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: A population-based study in Sweden. J Natl Cancer Inst 1994; 86: 761-769.
14. Fortes C, Mastroeni S, Sera F et al. Survival and prognostici variables of cutaneous melanoma observed between 1995 and 2000 at Istituto Dermopatico Dell'Immacolata (IDI-IRCCS), Rome, Italy. Eur J Cancer Prev 2006; 15: 171-177.
15. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanoma a regression-model analysis based on nationwide cancer registry data. Cancer 1988; 62: 2274-2280.
16. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
17. Ringborg U, Afzelius LE, Lagerlof B et al. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: A report from the Swedish Melanoma Study Group. Cancer 1993; 71: 751-758.
18. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed 1985; 19: 197-207.
19. Dickman PW, Sloggett A, Hills M. Hakulinen T. Regression models for relative survival. Stat Med 2004; 23: 51-64.
20. Kölmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant melanoma in Germany 1972-1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer 2002; 38: 1388-1394.
21. Liu W, Dowling JP, Murray WK et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142: 1551-1558.
22. Richard MA, Grob JJ, Avril MF et al. Melanoma and tumor thickness. Challenges of early diagnosis, Arch Dermatol 1999; 135: 269-274.
23. Kwalitetinstituut voor de Gezondheldszorg (CBO), Vereniging van Integrale Kankercentra (VIKC). Richtlijn. Melanoom van de huld. Alphen a/ d Rijn: Van Zuiden Communications B.V. 2005.
24. Beral V, Ramcharan S, Faris R, Malignant melanoma aind oral contraceptive use among women in California. Br J Cancer 1977; 36: 804-809.
25. Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 1983; 70: 827-831.
26. Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998; 138: 122-124.
27. Pfahlberg A, Hassan K, Wille L et al. Systematic review of case-control studies: Oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25: 309-315.
28. Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer 2003; 98: 1355-1361.
29. Naldi L, Altieri A, Imberti GL et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: A case-control study from Italy. Ann Epidemiol 2005; 15: 545-550.
30. Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer Treat Rev 2001; 27: 201-209.
31. Berwick M, Armstrong BK, Ben-Porat L et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97: 195-199.
32. Millen AE, Tucker MA, Hartge P et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1042-1051.
33. Le Marchand L, Saltzman BS, Hankin JH et al. Sun exposure, diet, and melanoma in Hawaii Caucasians. Am J Epidemiol 2006; 164: 232-245.
34. Stryker WS, Stampfer MJ, Stein EA et al, Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol 1990; 131: 597-611.
35. Koomen E, Joosse A, Herings R et al. Effect of statins on melanoma of the skin. Eur J Cancer (in press).
36. Kovacs FJ, Messingham KA. Influence of alcohol and gender on immune response. Alcohol Res Health 2002; 26: 257-263.
37. Shors AR, Solomon C, McTieman A, White E. Melanoma risk in relation to height, weight, and exercise (United States). Cancer Causes Control 2001; 12: 599-606.
38. Veierod MB, Thelle DS, Laake P, Diet and risk of cutaneous malignant melanoma: A prospective study of 50,757 Norwegian men and women. Int J Cancer 1997; 71: 600-604.
39. Florell SR, Boucher KM, Garibotti G et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005; 23: 7168-7177.
40. Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol 2007; 14: 3-8.
41. Bouman A, Heineman MJ, Faas MM. Sex hormones, and the immune response in humans. Hum Reprod Update 2005; 11: 411-423.
42. Thomas-Ahner JM, Wulff BC, Tober KL et al. Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage. Cancer Res 2007; 67: 3468-3474.
43. Mantovani A. Cancer: An infernal triangle. Nature 2007; 448: 547-548.
44. Schouten LJ, Straatman H, Kiemeney LA et al. The capture-recapture method for estimation of cancer registry completeness: A useful tool? Int J Epidemiol 1994; 23: 1111-1116.